Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial
Clinical trial NCT05554328 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT05554328
- Sponsor
- National Cancer Institute (NCI)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-04-25
- Primary completion
- 2028-10-01
- Enrollment
- 165
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.